A dark side to NS1 antibodies?

The NS1 protein of flaviviruses is taking center stage. Recent work has made it an attractive target for development of vaccines and immunotherapeutics. Cavazzoni and colleagues (2021. J. Exp. Med. https://doi.org/10.1084/jem.20210580) now reveal a dark side to NS1, linking it to the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Robbiani, Davide F., Růžek, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321876/
https://www.ncbi.nlm.nih.gov/pubmed/34319348
http://dx.doi.org/10.1084/jem.20211348
_version_ 1783730928907976704
author Robbiani, Davide F.
Růžek, Daniel
author_facet Robbiani, Davide F.
Růžek, Daniel
author_sort Robbiani, Davide F.
collection PubMed
description The NS1 protein of flaviviruses is taking center stage. Recent work has made it an attractive target for development of vaccines and immunotherapeutics. Cavazzoni and colleagues (2021. J. Exp. Med. https://doi.org/10.1084/jem.20210580) now reveal a dark side to NS1, linking it to the development of self-reactive antibodies.
format Online
Article
Text
id pubmed-8321876
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-83218762022-03-06 A dark side to NS1 antibodies? Robbiani, Davide F. Růžek, Daniel J Exp Med Insights The NS1 protein of flaviviruses is taking center stage. Recent work has made it an attractive target for development of vaccines and immunotherapeutics. Cavazzoni and colleagues (2021. J. Exp. Med. https://doi.org/10.1084/jem.20210580) now reveal a dark side to NS1, linking it to the development of self-reactive antibodies. Rockefeller University Press 2021-07-28 /pmc/articles/PMC8321876/ /pubmed/34319348 http://dx.doi.org/10.1084/jem.20211348 Text en © 2021 Robbiani and Růžek http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Robbiani, Davide F.
Růžek, Daniel
A dark side to NS1 antibodies?
title A dark side to NS1 antibodies?
title_full A dark side to NS1 antibodies?
title_fullStr A dark side to NS1 antibodies?
title_full_unstemmed A dark side to NS1 antibodies?
title_short A dark side to NS1 antibodies?
title_sort dark side to ns1 antibodies?
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321876/
https://www.ncbi.nlm.nih.gov/pubmed/34319348
http://dx.doi.org/10.1084/jem.20211348
work_keys_str_mv AT robbianidavidef adarksidetons1antibodies
AT ruzekdaniel adarksidetons1antibodies
AT robbianidavidef darksidetons1antibodies
AT ruzekdaniel darksidetons1antibodies

Ejemplares similares